

Funding Statement 2025

This statement outlines how EHA works with partners who provide funding to support the implementation of our annual workplan and arising activities.

EHA funding arises from multiple sources, the majority being pharmaceutical industry, but also some from public sources through the EU Erasmus + and health consultancies like Shift Health. In 2025 we also had income from registration fees from the conference arranged in Bucharest in September.

It is important to remember that EHA has a broad scope of objectives and we work to improve the quality of life for people in Europe living with Huntington's Disease.

In order to make funding partnerships work in practice, to ensure the integrity of both the funder and EHA is maintained, and to demonstrate to other stakeholders that our relationships are absolutely scrupulous, we commit to the below principles in relation to our funding:

MULTI-SOURCE

EHA commits to ensuring that our projects are supported by a consortium of funding partners, and that no individual company/organization provides more than 25 percent of our annual income in one year.

TRANSPARENT

A written agreement between the funder and EHA outlining the nature and amount of the funding and the period covered – is required before EHA will accept funding from any source. The funding sources will be acknowledged with thanks on relevant publications linked to an event/initiative. The amount of funding received and the sources are included in the EHA Annual Report and published separately on the EHA website within one month of the Annual Accounts being approved by the Annual General Assembly of the following year.

INDEPENDENT AND ETHICAL CODE OF CONDUCT

Relationships between non-governmental organizations (NGOs) and pharmaceutical and biotech companies can and should be based on equal partnership. Both sides must be prepared to move beyond the NGOs being passive recipients of money to a scenario where the two work together on policy development and practical initiatives, in the interests of the patients and their carers whom the NGO represents. While preserving its independence, NGOs should recognise that pharmaceutical and biotech companies have to be profitable, and have their own particular marketing agenda, to which no NGO should ever feel obliged to conform. Funding should be rejected if the alternative is compromising the NGOs independence in any way.

<https://eurohuntington.org/about-eha/collaborative-pharmaceutical-guidelines/>

ACKNOWLEDGEMENT OF FINANCIAL SUPPORT

EHA would like to acknowledge the below support in 2025:

INDUSTRY FUNDING	AMOUNT €	% INCOME
Wave Life Sciences	69.896€	13.96%
Roche	65.720€	13.13%
Ferrer	53.196€	10.63%
Novartis	49.923€	9.97%
uniQure	46.823€	9.35%
Atalanta	32.734€	6.54%
Prilenia	30.996€	6.19%
Harness	25.575€	5.11%
Alnylam	10.000€	2.00%
TRB	7.000€	1.40%
Horizon	4.769€	0.95%
Total: 396.632€		79.24%

NON-INDUSTRY FUNDING	AMOUNT €	% INCOME
Conference	53.200€	10.63%
HD-CAB	19.000€	3.80%
EU Erasmus+	12.000€	2.40%
Shift Health	11.383€	2.27%
HCD	5.925€	1.18%
Members	2.400€	0.48%
Total: 103.908€		20.76%

Total income: **500.540€**

Total percentage of industry funding: **79.24%**

Total percentage of non industry funding: **20.76%**